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NUTRIENT MIXTURE INHIBITS IN VITRO AND IN VIVO GROWTH 
OF HUMAN ACUTE PROMYELOCYTIC LEUKEMIA HL-60 CELLS
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Aim: Untreated acute promyelocytic leukemia is the most malignant form of acute leukemias, with median survival of less than one 
month. We investigated in vitro and in vivo synergistic effects of a nutrient mixture (NM) containing ascorbic acid, lysine, proline, 
and green tea extract, on acute promyelocytic leukemia HL-60 cells.  Methods: In vitro, the HL-60 cells were cultured and exposed 
to NM at doses 0–1000 μg/ml. Cell viability was assessed by Trypan blue dye exclusion test, matrix metalloproteinases (MMP) ex-
pression by gelatinase zymography, invasion through Matrigel and apoptosis by live green Poly Caspase Detection Kit. In vivo studies 
were carried out in athymic nude mice subcutaneously inoculated with HL-60 cells. Results: In vitro, NM exhibited a dose dependent 
reduction in cells viability. Zymography revealed matrix MMP-2 and phorbol 12-myristate 13-acetate induced MMP-9 expression. 
NM inhibited expression of both MMP in a dose dependent manner. Similar step-wise reduction in the Matrigel invasion by HL-
60 cells was also observed by this combination with incremental doses. Gradually increasing doses of NM induced significant apoptosis 
in HL-60 cells. In vivo, NM inhibited tumor growth by 50%. Conclusion: The results indicate that NM significantly suppresses tumor 
growth, decreases cell viability, inhibits MMP expression, Matrigel invasion and induces apoptosis in HL-60 cells.
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Acute promyelocytic leukemia (APL) is a unique 
subtype of acute myelogenous leukemia (AML) with 
distinct cytogenetic, clinical features and biological 
characteristics including abnormal accumulation 
of promyelocytes. APL is the most malignant form 
of AML and without treatment has median survival 
of less than a month [1, 2].
In our previous studies we have used a combination 
of nutrients (NM) containing several bioactive agents, 
such as ascorbic acid, lysine, proline and green tea 
extract, combined with other supporting nutrients 
on multiple cancer cell lines. The nutrient mixture 
has exhibited synergistic anticancer activity in vivo, 
in vitro in a number of cancer cell lines through inhibi-
tion of cancer cell growth, MMP expression, invasion, 
angiogenesis and metastasis [3–5]. 
Considering the efficacy of NM on other cancer cell 
lines, we aimed to analyze if NM had any effects on HL-
60 cells, a cell line which was originally obtained from 
an APL patient. The current study is designed to examine 
the in vitro effect of NM on viability of HL-60 cells, MMP 
expression, Matrigel invasion and apoptosis. In addition, 
we also studied effects of NM in vivo, on growth of HL-
60 cell line xenografted into athymic nude mice.
MATERIALS AND METHODS:
Leukemia cell line and cell culture. APL cell line 
HL-60, obtained from ATCC (American Type Culture 
Collection, Rockville, MD), was cultured in modified 
Dulbecco’s medium supplemented with 20% fetal bo-
vine serum, 100 μg/ml penicillin and 100 μg/ml strep-
tomycin. The media and sera used were obtained from 
ATCC, and penicillin, streptomycin were obtained from 
Gibco, BRL (Long Island, NY). 
Cell proliferation study. The cells were treated 
with the NM, dissolved in media and tested at 0, 10, 50, 
100, 500 and 1000 μg/ml in triplicate at each dose. Cell 
viability and cytotoxicity was assessed by Trypan blue 
dye exclusion test after 24 h as described in previous 
studies [6, 7].
Gelatinase zymography. Gelatinase zymography 
was used to determine the MMP activity in conditioned 
media. Zymography was performed in 10% Novex 
precast SDS-polyacrylamide gel (Invitrogen Corpo-
ration, Carlsbad, CA) in the presence of 0.1% gelatin 
under non-reducing conditions. Phorbol 12-myristate 
13-acetate (PMA), 100 ng/ml, was added to the cells 
to induce MMP-9 secretion. Other steps were followed 
as described in previous publications [6, 7].
Invasion using Matrigel. Invasion studies were 
conducted as described in the prior studies [6, 7] us-
ing Matrigel™ (Becton-Dickinson, Franklin Lakes, NJ) 
inserts in 24-well plates. 
Apoptosis. Apoptosis was determined by the 
method described in the live green Poly Caspase 
Detection Kit at different doses of NM. Cells were 
challenged with the NM at 0, 50, 100, 500 and 
1000 μg/ml concentration and incubated for 24 h. The 
culture was washed with PBS and treated with caspase 
reagent as specified in the manufacturer’s protocol 
(Molecular Probes Image–IT™ Live green Poly Cas-
pase Detection Kit 135104, Invitrogen). Cells were 
photographed under a fluorescence microscope and 
counted. Green colored cells represent viable cells, 
while yellow orange colored cells represent early 
apoptosis and red color represents late apoptosis. 
In vivo study. Male athymic nude mice (NCr-nu/nu), 
approximately 6 weeks of age, were purchased from 
Simonsen Laboratories, Gilroy, CA and maintained 
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in microinsulated cages under pathogen-free conditions 
on a 12h light/12h dark schedule for a week. All animals 
were cared for in accordance with institutional guidelines 
for the care and use of experimental animals. After hous-
ing for a week, the mice (n = 10) were inoculated with 
3x106 HL-60 cells in 0.2 ml of PBS and 0.1 ml of Matrigel 
(BD Bioscience, Bedford, MA) in the right flank. After 
injection, the mice were randomly divided in two groups; 
group A was fed regular diet while group B was fed the 
regular diet supplemented with 0.5% of NM. During the 
study, the mice consumed, on an average, 4 g of their 
respective diets per day. Thus, the supplemental mice 
received approximately 20 mg of NM per day. After 
4 weeks, the mice were sacrificed and the tumors were 
excised and processed for histology. Tissue samples 
were fixed in 10% buffered formalin, embedded in par-
affin and cut at 4–5 μm. Sections were deparaffinized 
through xylene and graduated alcohol series to water and 
stained with hematoxylin and eosin (H&E) for evaluation 
using a standard light microscope.
Statistical analysis. Results were expressed 
as means ± SD for the groups. Data was analyzed 
by independent sample “t” test.
RESULTS
In vitro studies.
Cell proliferation study. NM was non-toxic to HL-
60 acute promyelocytic leukemia cells at 10 μg/ml and 
exhibited a dose response toxicity with further increase 
in concentrations (Fig. 1).
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Fig. 1. Effect of NM on HL-60 viability
Gelatinase zymography. Zymography demonstrat-
ed a faint band corresponding to MMP-2 and enhanced 
secretion of MMP-9 by cells when treated with PMA 
(100 ng/ml). NM inhibited the expression of MMP-2 and 
MMP-9 in a dose dependent fashion, with virtually total 
inhibition at 1000 μg/ml as shown in Fig. 2, a, c. Densi-
tometry analysis shows gradually decreasing MMP-2 ex-
pression with increasing concentration of NM (R2 = 0.925) 
(Fig. 2, b) Similarly, expression of MMP-9 was inhibited 
in a dose dependent fashion with complete inhibition 
at 1000 μg/ml (R2 =0.834) (Fig. 2, d).
Invasion through Matrigel. The NM significantly 
inhibited invasion of HL-60 cells through Matrigel. 
Compared with control, the NM showed increasing 
inhibition of invasion, starting at 100 μg/ml (18%) and 
92% at 500 ug/ml. The invasion was totally blocked 
at 1000 μg/ml. (Fig. 3).
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Fig. 2. Effect of NM on MMP-2 and MMP-9 expression by HL-
60 cells: a, faint band corresponding to MMP-2 in untreated 
HL-60 cells; intensity of expression decreases with increasing 
concentrations of NM (1 — marker, 2 — control, 3–7 — NM doses 
10, 50, 100, 500, 1000 μg/ml respectively); b,  densitometry 
shows the effect of NM on relative activity of MMP-2 in HL-
60 cells is reduced as the dose increases; c,  effect of NM on PMA 
(100 ng/ml) treated HL-60 cells; NM exhibiting dose dependant 
decrease in MMP-9 expression (1 — marker, 2 — control, 3–7 — 
NM doses 10, 50, 100, 500, 1000 μg/ml respectively); d, den-
sitometry shows the effect of NM on relative activity of MMP-9
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Fig. 3. Effect of NM on Matrigel invasion of HL-60 cells. Matrigel 
invasion significantly decreased by NM in dose dependent manner
Apoptosis (live green caspases detection kit). 
Dose dependent apoptosis of HL-60 cells was evident with 
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the NM challenge. The extent of apoptosis increased sig-
nificantly with increasing doses of NM up to 1000 μg/ml. 
(Fig. 4, a, b). Quantitative analysis of live, early and late 
apoptotic cells is shown (Fig. 4, c). Moderate apoptosis 
with 64% live cells and 18% apoptotic cells was seen 
with exposure to 50 μg/ml NM. Percentage of dead cells 
gradually increased up to 58% at 1000 μml while the 
percentage of live cells decreased with increase in dose 
of NM from 65% to 29% at 1000 μg/ml.
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Fig.  4.  Photomicrographs of  apoptos is  induct ion 
in HL-60 Cells by NM (Live green caspase detection kit): a, 
control; b, NM 1000 μg/ml; c, quantitative analysis of live, early 
and late apoptotic cells
In vivo studies. HL-60 xenografts developed 
in NM supplemented nude mice weighed 50% lower than 
those developed by the control group of mice. Nude mice 
from both groups showed no loss in body weight over the 
study period. The tumors from both groups were reported 
to be histologically similar. They were comprised of pleo-
morphic cells with abundant cytoplasm and vesicular 
nuclei. Abundant mitotic figures were noted. No capsule 
was noted. Tumor cells were forming small packets and 
sheets that were infiltrating within the surrounding tissues. 
Within control group, there were multifocal areas of necro-
sis that comprised less than 1% of the total area. Within 
the test group, there were multifocal areas of necrosis 
that comprised less than 10% of the tumor mass (Fig. 5).
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Fig. 5. Tumor histology:  a, control group; b, NM supplemented 
group. Increased areas of necrosis seen within tumor tissue from 
animals in the NM supplemented group 
DISCUSSION
The results of the present study clearly indicate 
the benefits of exposure of the NM formulated using 
several potential bioactive agents. In vitro, addition 
of NM resulted in decreased cell viability, inhibition 
of MMP expression, and invasion through Matrigel, 
as well as increased apoptosis in HL-60 cells. In vivo, 
the NM inhibited growth of HL-60 xenografts in athymic 
nude mice. The observation that the NM inhibited ex-
pression of MMP-2 and MMP-9 supports the argument 
that this could be one of the mechanisms by which the 
NM inhibits invasion of these cells into Matrigel. 
Although, it is well accepted that MMPs are involved 
in tumor growth, angiogenesis, invasion and metastasis 
of solid tumors [8, 9], researchers continue to explore the 
role of MMPs in hematological malignancies. It has been 
suggested that an important aspect of favorable prog-
nosis in myeloid leukemias is the cell capacity to store 
MMPs. Higher MMP storage may be linked to maturation 
of normal myelocytes [10]. Moreover, activation of MMP 
is a required initial step for malignant cells to cross the 
barriers within bone marrow and enter circulation be-
fore invading other tissues. Some studies indicate that 
myeloid leukemia patients with higher MMP-2 levels 
demonstrate significantly lower survival rate than the pa-
tients with lower MMP-2 levels [11]. In addition, increased 
level of MMP-2 activity was noted in leukemia patients 
with poor response to chemotherapy [12]. Similarly, 
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patients with lower MMP-9 levels were shown to have 
higher survival than otherwise [13]. Annabi et al. [14] 
have reported the specific role of epigallocatechin gallate 
in suppressing MMP-9 secretion and the significance 
of their angio-suppressive action in APL.
While researchers continue to explore synthetic 
compounds to target specific MMP enzymes in cancer 
therapies, we think that one of the most promising ap-
proaches to cancer treatment would be targeting multiple 
steps involved in cancer growth and progression. Thus, 
by encapsulating the tumor, strengthening of connective 
tissue, preventing angiogenesis, and inducing apoptosis; 
we believe that cancer progression could be arrested. 
Our previous research has proven that control of the 
proteolytic degradation of extracellular matrix using 
nutrient combination provides an opportunity to address 
these common mechanisms [15]. Many, if not all, these 
mechanisms could play a role in hematological malignan-
cies as well. In this study we have used this approach 
to evaluate effects of NM on HL-60 cells representing 
APL. As results indicate, MMP-2 and MMP-9 expres-
sion and Matrigel invasion by HL-60 cells was inhibited 
by NM in a dose dependent fashion suggesting that the 
NM has significant bioactivity on HL-60 cells.
Most APL patients are treated with all-trans reti-
noic acid (ATRA) and arsenic trioxide in combination 
with chemotherapy. Although it increases the chance 
of favorable prognosis, it fails to achieve a complete and 
durable remission. ATRA resistance is known to develop 
in lab and clinical settings [16]. In addition, ATRA therapy 
is associated with its own unique and serious side effect 
called as retinoic syndrome or differentiation syndrome. 
It is characterized by pleural and pericardial effusion, 
edema, dyspnea and pulmonary infiltrates. And post re-
mission therapy is crucial in ensuring disease-free survival. 
Despite all the measures, 20–30% of APL patients relapse 
and require further treatment with more arsenic oxide and 
stem cell transplant before palliative care is considered. 
Arsenic trioxide can cause dangerous arrhythmias [1, 2].
In the present study, exposure to 0.5% dietary 
supplement of the NM for four weeks neither affected 
the gain in body weight nor the food consumption 
by experimental mice. Further, in a previous in vivo 
study addressing the safety issues, we found that 
gavaging adult female ODS rats with the NM (at 30, 
90, or 150 mg per day for seven days), had neither 
adverse effects on vital organs such as heart, liver, 
and kidney, nor on the associated functional serum 
enzymes. Therefore, indicating that the mixture is safe 
to use even at these higher doses, which exceed the 
normal equivalent doses of the nutrients [17].
The results of the present study show that supple-
mentation with the NM formulated using multiple bioac-
tive agents was effective by many parameters (decreased 
cell viability, inhibition of MMPs (2 and 9) expression, and 
Matrigel invasion,  increased apoptosis of HL-60 cells, 
and 50% decrease in tumor weight in NM treated mice 
versus control group) and substantiate the potential 
of NM as a possible therapeutic combination.
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